InvestorsHub Logo
Followers 14
Posts 649
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Saturday, 12/05/2015 8:47:36 PM

Saturday, December 05, 2015 8:47:36 PM

Post# of 463112
My hunch is based on purely circumstantial info... as follows:
#1) It was revealed today that he knows all about AVXL.; and
#2) one of his mentored students, now an expert in epilepsy is none other than Dad of Marc and Max....

So there is no proof, but I was thinking what are the chances of the two conditions above being true, and assuming the two consulted on the topic and Devinsky not being invested?...

"Devinsky's epilepsy research interests include translational therapies, sudden unexpected death in epilepsy (SUDEP), devices to deliver drugs directly to the brain, quality of life, cognitive and behavioral issues in epilepsy, surgical therapy, and new medications. Other areas of active interest include autism, tuberous sclerosis, and head trauma.

Devinsky serves as the director of the Phenome Core for the Epilepsy Phenome/Genome Project, funded by an NIH multi-institutional grant. Devinsky and his co-investigators are conducting studies of several investigational antiepileptic medications such as topiramate, tiagabine, lamotrigine, vigabatrin, oxcarbazepine, and remacemide, as well as vagal nerve stimulator implantation. He is also collaborating with other researchers to develop a device to deliver antiepileptic drugs directly to the brain to treat seizures.

He was involved in pivotal drug studies for felbamate, oxcarbazepine, intravenous valproate and other drugs. He was the lead investigator of the Quality of Life in Epilepsy group that developed the four inventories that were translated into many languages and used in over 150 academic studies.[2]"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News